 Home > Active Ingredient News > Immunology News > Interpretation of Phase 2 clinical trials of hydroxychloroquine

Interpretation of Phase 2 clinical trials of hydroxychloroquine

 Last Update: 2022-08-15
 Source: Internet
 Author: User

Tags

equilibrium phase diagram

kappa light chain

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Patients with advanced (defined as unresectable or metastatic) v-Raf mouse sarcoma virus oncogene homolog B V600 (BRAFV600) mutated melanoma patients who were previously treated with v-Raf mouse sarcoma virus oncogene homolog B (BRAFV600) )/mitogen-activated protein kinase (MEK) inhibitors and programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immunotherapy have progressed after immunothera.

In a prospective phase 2 clinical trial of 25 patients who discontinued BRAF-/MEK inhibitor therapy at least 12 weeks prior to enrollment, the objective response rate (ORR) was 32% and the disease control rate (DCR) was 7

Hydroxychloroquine prevents autophagy-driven resistance and improves the efficacy of BRAF-/MEK-inhibitors in preclinical melanoma mode.

Following the safety run-in phase, in the Phase 2 portion of the trial, patients were randomly assigned between prior treatment with dabrafenib, trametinib, and hydroxychloroquine (experimental arm) or dabrafenib and trametinib, with the potential to add hydroxychloroquine upon documented tumor progression Chloroquine (concurrent control grou.

CONSORT plot (AE, adverse event; DAB, dabrafenib; HCQ, hydroxychloroquine; pt(s), patient; PD, progressive disease; TRA, trametinib):

Best objective response in the intent-to-treat population:

In conclusion, ongoing studies are investigating this drug combination in less pretreated populatio.

Selection of patients to receive hydroxychloroquine can be based on the expression of autophagy markers (eg, microtubule-associated protein 1 light chain 3β) on tumor samples at baseline or on treatment, while patients without this signature can receive other treatments

References: Awada G, Schwarze JK, Tijtgat J, Fasolino G, Kruse V, Neyns.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.